Bionaut Labs

Company Overview

Snapshot

Founded in January 2016 by Aviad Maizels, Michael Shpigelmacher, and Alexander Shpunt, Bionaut Labs operates with 11–50 employees. The company has raised $69.2 million across 3 funding rounds from 15 investors. In February 2024, Bionaut Labs secured an extension round of funding, with participation from OurCrowd.

Business overview

Bionaut Labs is a biotechnology startup developing a precision medicine treatment modality for central nervous system (CNS) disorders. The company utilizes remote-controlled microscale robots, called Bionauts, to deliver biologics, nucleic acids, or small molecule therapies directly to targeted CNS disease areas. This approach aims to achieve enhanced efficacy and safety compared to traditional treatment methods by enabling localized brain targeting. Bionaut Labs is initially focusing on indications such as gliomas and Huntington's disease, leveraging custom-engineered therapeutic micro-robots that precisely deliver payloads to specific locations within the body.

Strategic signal

Bionaut Labs' February 2024 extension funding round, involving investors like OurCrowd and Upfront Ventures, signals a critical step towards advancing its micro-robot technology into clinical trials. This development is significant for the Health Tech & Life Sciences sector, particularly in drug delivery and neurology, as it validates the potential for a novel, minimally-invasive approach to treating complex CNS disorders. For investors, it indicates continued confidence in the company's innovative platform and its progression towards commercialization, despite the company's non-active status as of June 2026.

Company Intelligence Q&A

What is the current operational status of Bionaut Labs?

Bionaut Labs ceased to operate in June 2026, and is currently listed as Non Active.

When was Bionaut Labs founded and by whom?

Bionaut Labs was founded in January 2016 by Aviad Maizels, Michael Shpigelmacher, and Alexander Shpunt.